Background {#Sec1}
==========

Lung cancer is the leading cause of cancer related death worldwide, including about 85% non-small cell lung cancer (NSCLC) \[[@CR1]\]. Platinum-based chemotherapy had long been standard treatment for advanced NSCLC, with only about 7.9 months median overall survival (OS) \[[@CR2]\]. Target therapy has already reformed the treatment of NSCLC harboring driver oncogene mutation, which significantly prolong the survival time \[[@CR3]\]. Meanwhile, the progression of immunotherapy in recent years has also greatly promoted the treatment of driving gene negative NSCLC, with longer survival and miner adverse reaction than chemotherapy \[[@CR4]\].

To our knowledge, through eliminating mutated cell, cytotoxic T lymphocyte (CTL) can prevent cancer's development and progression \[[@CR5]\]. CTL's function is regulated by complicated immune signal pathways \[[@CR6]\]. In cancer immunity, T cell receptor (TCR) recognizes major histocompatibility complex (MHC) with cancer-specific antigen as first signal to activate CTLs. And the second signal is from costimulatory factors, also called immune checkpoints, including stimulators for maintaining activation and inhibitors for preventing over-activation. For example, programed cell death-1 (PD-1) is such kind of inhibitor, which expressed in activated CTLs. Once PD-1 binds to its ligand, programed cell death ligand 1 (PD-L1) highly expressed in tumor cell's (TC) membrane, CTL's recognition to TCs would be suppressed, so that TCs could achieve self-adaption and escape from immune elimination \[[@CR7]\]. Accordingly, immune checkpoint inhibitors (ICIs) can block that kind of pathways and rebuild the CTL's ability to clear malignant cells.

Efficacy of ICIs, targeting in PD-1/PD-L1 axis, in NSCLC's clinical treatment has been proved a lot, from second line to first line, even in early stage patients \[[@CR8]--[@CR12]\]. Long-term follow-up data demonstrated immunotherapy has great potential for long-term response \[[@CR13]\]. However, limited beneficiary population and drug resistance are hindering the further development of immunotherapy \[[@CR14]\]. With deeper research on anticancer immunity, novel immune checkpoint inhibitors are desired to expand beneficiary population from immunotherapy \[[@CR15]--[@CR18]\]. Herein, we summarize the novel therapies of checkpoint inhibitors in NSCLC treatment and some other potential immunotherapy to provide a conspectus for novel immunotherapy in NSCLC and perspective for the future in anti-cancer treatment.

Immune checkpoint inhibitors in advanced NSCLC {#Sec2}
==============================================

Pembrolizumab, nivolumab and atezolizumab {#Sec3}
-----------------------------------------

Immune checkpoint inhibitors have made a great progression in advanced NSCLC without positive driver mutation in recent years \[[@CR8]--[@CR12]\]. The efficacy of single agent therapy with ICIs is proved from second line to first line. Due to the efficacy and safety demonstrated by pembrolizumab in keynote 001 \[[@CR9]\], FDA approved it as an optional second-line treatment for advanced NSCLC. Subsequently, keynote 010 further proved that compared with docetaxel, PD-L1 positive (tumor proportion score, TPS ≥ 1%) patients could gain significantly survival benefits from pembrolizumab, especially those with TPS ≥ 50%, and the incidence of adverse reactions was lower \[[@CR10]\]. Moreover, results of keynote 024 and 042 supports the use of pembrolizumab monotherapy as first line treatment for PD-L1 positive NSCLC patients, especially for high expression population \[[@CR19], [@CR20]\]. Despite lacking evidence of benefits from first line treatment, patients can also obtain survival and life quality benefits from monotherapy with nivolumab or atezolizumab after failing in first line treatment because of the positive results of checkmate 017/057 and OAK \[[@CR11], [@CR12]\] (Table [1](#Tab1){ref-type="table"}).Table 1Posted results of monotherapy with pembrolizumab, atezolizumab, nivolumab, durvalumab and avelumab in advanced NSCLCIdentifierTrialsAgentphaseIndicationPopulationArmsBiomarkersORRmPFSmOSmDORAdverse effects (grade ≥ 3)NCT01295827Keynote 001PembrolizumabISecond lineAdvanced NSCLCPembrolizumabRegardless PD-L119.40%3.7 m12.0 mNR9.50%PD-L1 ≥ 50%45.20%6.3 mNR12.5 mNANCT01905657Keynote 010PembrolizumabII/IIISecond linePreviously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cellsPembrolizumab = 2 mg/kgPD-L1 ≥ 50%30.00%5.0 m14.9 mNR13.00%Pembrolizumab = 10 mg/kgPD-L1 ≥ 50%29.00%5.2 m17.3 mNR16.00%DocetaxelPD-L1 ≥ 50%8.00%4.1 m8.9 m8 m35.00%NCT02142738Keynote 024PembrolizumabIIIFirst linePreviously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no mutation of EGFR or ALKPembrolizumab 200 mg/3 weeksPD-L1 ≥ 50%44.80%10.3 mNRNR26.60%Platinum-based chemotherapy27.80%6.0 m14.5 m6.3 m53.30%NCT02220894Keynote 042PembrolizumabIIIFirst linePreviously untreated advanced non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with ECOG 0 or 1, and a PD-L1 TPS of 1% or greaterPembrolizumabPD-L1 ≥ 50%39.50%7.1 m20.0 m20.2 m17.80%PD-L1 ≥ 20%33.40%6.2 m17.7 mPD-L1 ≥ 1%27.30%5.4 m16.7 mPlatinum-based chemotherapyPD-L1 ≥ 50%32.00%6.4 m12.1 m10.8 m41.90%PD-L1 ≥ 20%28.90%6.6 m13.0 m8.3 mPD-L1 ≥ 1%26.50%6.5 m12.1 m8.3 mNCT02008227OAKAtezolizumabIIISecond linePreviously treated NSCLCAtezolizumabITT population14.00%2.8 m13.8 m16.3 m15.00%Docetaxel13.00%4.0 m9.6 m6.2 m43.00%NCT01642004/NCT01673867Checkmate 017/057NivolumabIIISecond linePreviously treated patients with advanced squamous or nonsquamous non--small-cell lung cancerNivolumabNANA2.56 m11.1 mSquamous: 25.2 m10.00%Non-squamous: 17.2 mDocetaxelNA3.52 m8.1 mSquamous: 8.4 m55.00%Non-squamous: 5.6 mNCT01693562Study 1108DurvalumabI/IISecond linePretreated NSCLC EGFR/ALK wild typeDurvalumab from 0.1 to 10 mg/kg q2w or 15 mg/kg q3wPD-L1 ≥ 25%25.30%2.8 m15.4 mNR10.00%PD-L1\<25%6.10%1.5 m7.6 mFirst lineTreatmentnaïve advanced NSCLC EGFR/ALK wild typeDurvalumab10 mg/kg q2wPD-L1 ≥ 25%28.60%4.0 m21 mNR9.00%PD-L1\<25%11.00%NANANCT02220894ATLANTICDurvalumabIIThird lineHeavily pretreated advanced NSCLC EGFR/ALK positiveDurvalumabPD-L1 ≥ 25%14.10%1.9 m13.3 m7.4 m5.40%PD-L1\<25%3.60%1.9 m9.9 mNRHeavily pretreated advanced NSCLC EGFR/ALK wild type or unknownDurvalumabPD-L1 ≥ 90%30.90%2.4 mNRNR17.60%PD-L1 ≥ 25%7.50%3.3 m10.9 m8.20%PD-L1\<25%3.30%1.9 m9.3 mNCT02766335Lung-MapDurvalumabIISecond linePretreated NSCLC EGFR/ALK wild typeDurvalumabPD-L1 ≥ 25%14.30%NA10.7 mNR34.00%PD-L1\<25%6.90%NA11.6 mDocetaxelNA6.70%NA7.7 mNRNANCT02125461PACIFICDurvalumabIIISecond lineUnresectable stage III NSCLC after chemoradiation Regardless of PD-L1 statusDurvalumabNA28.40%16.8 m23.2 mNR29.90%Placebo16.00%5.6 m14.6 m26.10%NCT02395172JAVELIN Lung 200AvelumabIIISecond linePlatinum-treated patients with advanced NSCLCAvelumabPD-L1 ≥ 1%19.00%3.4 m11.4 mNR10.00%Patients can obtain survival and life quality benefits from monotherapy with tolerable adverse reactions*ORR* objective response rate, *mPFS* median Progression Free Survival, *mOS* median Overall survival, *mDOR* median Duration of Response, *NR* not reached, *NA* nona, *ITT* intend to treat

Though single agent therapy with ICIs has already reformed the treatment strategy of advanced NSCLC, there is still a great proportion of patients could not respond \[[@CR21]\]. Combination strategies may help to overcome the resistance (Table [2](#Tab2){ref-type="table"}).Table 2Posted results of first-line combination regimen trials for pembrolizumab, nivolumab, and atezolizumab in advanced NSCLCIdentifierTrialsAgentPhasePopulationArmsBiomarkersORRmPFS1 year\
PFS ratemOS1 year OS ratemDORAdverse Effects Rate (≥ grade 3)NCT02039674Keynote 021PembrolizumabIIUntreated metastaticNon-squamous NSCLCWithout EGFR/ALK alterationPembrolizumab + platinumRegardless PD-L155.00%24 mNANRNANA39.00%Platinum29.00%9.3 m21.1 m26.00%NCT02578680Keynote 189PembrolizumabIIIUntreated metastaticNon-squamous NSCLCWithout EGFR/ALK alterationPembrolizumab + platinumRegardless PD-L147.60%8.8 m34.10%NR69.20%11.2 m67.20%Platinum18.90%4.9 m17.30%11.3 m49.90%7.8 m65.80%NCT02775435Keynote 407PembrolizumabIIIUntreated metastatic, squamous NSCLCPembrolizumab + platinumRegardless PD-L157.90%6.4 mNA15.9 m65.20%7.7 m69.80%platinum38.40%4.8 mNA11.3 m48.30%4.8 m68.20%NCT02477826Checkmate 227NivolumabIIIUntreated metastaticNon-squamous NSCLCWithout EGFR/ALK alterationNivolumab + platinumTMB ≥ 10mut/Mb60.50%NA27.00%NANANANANivolumab + ipilimumab45.30%7.2 m45.00%31.20%Platinum27.00%5.4 m13.20%36.10%NCT02657434Impower 131AtezolizumabIIITreatment-naïve Stage IV squamous NSCLCAtezolizumoab + carboplatinITT population49.00%6.3 m24.00%14.0 m55.60%NA69.00%Carboplatin41.00%5.6 m12.00%13.9 m56.80%58.00%2NCT02657434Impower132Atezolizumab12IIINon-squamous NSCLCWithout EGFR/ALKalterationUntreated metastaticAtezolizumoab + carboplatinITT population47.00%7.6 m33.70%18.1 m59.60%10.1 m69.00%Carboplatin32.00%5.2 m13.6 m59.00%NCT02659059Checkmate 568NivolumabIIUntreated metastaticNon-squamous NSCLCWithout EGFR/ALK alterationNivolumab plus low-dose ipilimumabPD-L1 \< 1%41.00%6.8 m52%^a^NANANA29.00%PD-L1 ≥ 1%15.00%2.8 m32%^a^TMB ≥ 10 mut/Mb44.00%7.1 m55%^a^TMb \< 10 mut/Mb12.00%2.6 m31%^a^Combination strategies may help patients overcome NSCLC resistance that ICI monotherapy face with*ORR* objective response rate, *PFS* Progression Free Survival, *OS* overall survival, *DOR* Duration of Response, *ITT* intend to treat, *TMB* tumor mutation burden^a^6-month PFS rate

It is reported that platinum-based chemotherapy can contribute to sensitization of tumor to ICIs through increasing CD8+ T cell infiltration \[[@CR22]\]. Keynote 021 is the first trial which succeed in combining platinum-based chemotherapy and ICIs for treat naïve pan-negative advanced NSCLC \[[@CR23]\]. Regardless of PD-L1's expression, the ORR is almost double in pembrolizumab plus chemotherapy comparing to chemotherapy, while the risks of progression and death are decreasing to only a half with the toxicity safely controlled. After that, keynote 189 and 407 successively announced their similar results in squamous and non-squamous cell carcinoma \[[@CR24], [@CR25]\], which have further strengthened evidences for combining ICIs and platinum-based chemotherapy as first line treatment. Comparing with keynote 024/042, for patients with low or negative PD-L1 expression (TPS \< 50%), the strategy of combination with chemotherapy is safer and more cost-effective \[[@CR26]\]. Additionally, Impower 131 and 132 reached their primary endpoint, proving that patients can gain more survival benefits and less risks from the combination of atezolizumab and chemotherapy rather than monotherapy with chemical agents \[[@CR27], [@CR28]\]. Interestingly, in the exploring analysis, both trials are observed that in PD-L1 high expression and negative group, combination presents better PFS than monotherapy, while in PD-L1 low expression group, there is no significant difference between them, indicating the biomarkers for patient selection need to be explored more. After failed in the competition of monotherapy, exploring combination may help nivolumab to break the dilemma in first line treatment. In ASCO 2018 meeting, Borghaei et al. announced a sub-group analysis of checkmate 227, nivolumab plus chemotherapy has a trend in improving PFS comparing to chemotherapy in patients with negative PD-L1 expression (HR = 0.74 \[95% CI 0.58, 0.94\]) \[[@CR29]\]. Furthermore, nivolumab plus chemotherapy can significantly improve 1-year PFS rate (27% vs 8%; HR = 0.56 \[95% CI 0.35, 0.91\]) in those patients harboring high tumor mutation burden (TMB ≥ 10 Mut/Mb) than chemotherapy, suggesting that high TMB is a good predictor for benefits of combination \[[@CR29]\].

Cytotoxic T-lymphocyte association protein 4 (CTLA-4) is another negative immune checkpoint \[[@CR7]\]. Differ to PD-1 pathway, CTLA-4 pathway inhibits T cell in the initial stage of activation \[[@CR30]\]. Thence, blocking both PD-1 and CTLA-4 pathways could make synergistic effects, which could awake more CTLs in the initial stage of immunity and recover the immune activity in the late stage. Ipilimumab is a human-IgG1 antibody targeting against CTLA-4. The combination of nivolumab and ipilimumab was evaluated in several trials. After efficacy and safety were confirmed in checkmate 012, checkmate 227 was initialed for exploring more evidences \[[@CR31]\]. Regardless PD-L1's status, double ICIs can significantly improve ORR (45.3% vs 26.9%) and median PFS (7.2 m vs 5.4 m) comparing to chemotherapy in high TMB group. It is worth mentioned that combination of two ICIs can achieve higher 1-year PFS (45% vs 27%) than the combination of ICIs and chemotherapy in PD-L1 negative patients with high TMB. Safety is also satisfactory. 31.2% patients in combination group suffered from grade 3/4 AEs, while 36.1% in chemotherapy group \[[@CR32]\]. Furthermore, checkmate 568 recently confirmed that PD-L1 positive (TPS ≥ 1%) and high TMB (≥ 10 Mut/Mb) are both independent biomarkers for better effects prediction in such combination as first line treatment \[[@CR33]\].

Durvalumab and avelumab {#Sec4}
-----------------------

Durvalumab was first evaluated as a single agent in a large phase 1/2 study in advanced solid tumor patients \[[@CR34]\], including refractory advanced NSCLC (NCT01693562). According to prior lines of therapy, the ORR was 27.1% in treatment-naïve vs 18.8% in patients pretreated with platinum-based chemotherapy (second-line). High PD-L1 expression was associated with better response rates (25.3%; 39/154 patients) compared to low PD-L1 expression patients (6.1%;7/115 patients). Antonia et al. \[[@CR35]\], reported that according to the line of treatment, the ORR was 26.1% in high PD-L1 vs 4.2% in low PD-L1 in platinum-refractory patients, and 22.0% in high PD-L1 vs 6.1% in low PD-L1 in third or later lines. S1400A Lung-Map umbrella phase 2 trial (NCT02766335) showed durvalumab having an ORR of 14.3% in ≥ 25% PD-L1 expression (n = 14) and 6.9% in low/negative PD-L1 (TPS ≤ 25%) (n = 25) \[[@CR36]\]. ATLANTIC phase2 study (NCT02087423) showed PD-L1 expression ≥ 25% with a better median PFS than low/negative PD-L1 population (3.3 m vs 1.9 m) \[[@CR37]\]. In a heavily pretreated EGFR/ALK wild-type or unknown population, durvalumab demonstrated activity and durable responses. Trials of durvalumab combination regimens initiated, owing to the great success of durvalumab in second-line treatment as single agent. Avelumab is one of the last PD-L1 inhibitors to access the market, a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds PDL1 and inhibits its binding to PD-1 \[[@CR38]\]. JAVELIN Lung 200 is the first phase 3 trial of avelumab in patients with platinum pretreated NSCLC as monotherapy. Though median overall survival did not differ between avelumab and docetaxel group(11.4 m vs 10.3 m)in full analysis set population (FAS), post hoc analyses identified that specific populations who could benefit from anti-PD-1 or anti-PD-L1 antibodies. In PD-L1 population,median overall survival in subgroup TPS ≥ 80% and ≥ 50% was 17.1 months and 13.6 months in the avelumab group, comparing with 9.2 months in the docetaxel group \[[@CR39]\]. These results indicate that most patients with high PD-L1 expression can achieve improved overall survival if given avelumab.

Durvalumab is currently being investigated in combination with different immunotherapies, in the majority of cases with tremelimumab. Durvalumab in combination with tremelimumab was initially assessed in a phase 1/2 study (006, NCT02000947) in 102 treatment-naïve NSCLC patients \[[@CR40]\]. Durvalumab demonstrated clinical activity with an ORR of 17% \[95% CI 9--29\]). Based on the safety and activity, durvalumab 20 mg/kg q4w plus tremelimumab at 1 mg/kg were the recommended dose for phase 3 trials. The phase 3 MYSTIC trial (NCT02453282) enrolled 1092 advanced EGFR/ALK wild-type treatment-naïve NSCLC patients to compare durvalumab plus tremelimumab vs durvalumab vs SoC (platinum-based chemotherapy). In July 2017, MYSTIC trial did not meet the primary endpoint of PFS compared to chemotherapy. The study is continuing as planned to assess the primary endpoint of OS, PFS \[[@CR41]\]. Classically, platinum-doublet chemotherapy has been the SoC as first-line therapy for advanced NSCLC, improving survival and quality of life in treatment-naïve patients. However, recently single agent PD-1 inhibitor demonstrated better outcomes compared to platinum-based chemotherapy in ≥ 50% PD-L1 tumors \[[@CR42]\], as well as in combination with platinum-based chemotherapy for nonsquamous population, regardless of PD-L1 expression \[[@CR23], [@CR43]\]. Based on this potential synergism, several studies are currently evaluating ICI-chemotherapy combinations of durvalumab. For now, the limited evidence available is insufficient to establish the clinical impact of ICIs for EGFR and ALK-positive patients. The population harboring a driver molecular alteration such as an EGFR mutation is generally excluded from the majority of immunotherapy clinical trials. The only data available are derived from subgroup analyses from the phase 3 study with single-agent durvalumab in previously-treated populations, which showed no clear benefit in a small number of EGFR mutated patients \[[@CR12], [@CR42], [@CR44]\], and with an insufficient basis to draw definite conclusions. The ALK positive population has also been widely excluded from the majority of immunotherapy clinical trials. Several ongoing studies are evaluating the safety and efficacy of different ICIs as a single agent or in combination with an ALK TKI, however no solid evidence has been reported to date \[[@CR37]\]. In the phase 1b TATTON study (NCT02143466) the combination durvalumab plus osimertinib was evaluated in EGFR-mutated patients. However, due to the high incidence of interstitial lung disease (ILD), this study arm was stopped prematurely, as was the phase 3 CAURAL trial (NCT02454933) assessing osimertinib plus durvalumab vs osimertinib in second-line EGFR-mut NSCLC patients. The phase II ATLANTIC trial testing durvalumab as third-line treatment included the largest cohort of EGFRmutant patients treated with ICI (n = 98) after progression on EGFR TKI and chemotherapy. According to PD-L1 expression (\< 25% or ≥ 25%), durvalumab achieved a RR of 3.6% and 14.1%, a similar median PFS 1.9 months and a median OS of 9.9 months and 13.3 months, respectively. As the data showed, even patients with heavily pretreated, EGFR/ALK mutation-positive advanced NSCLC may also benefit from greater than or equal to third-line PD-1/PD-L1 inhibitors treatment, with durable efficacy and a promising effect on OS. The most impressive results for immunotherapy and radiation, have come from the phase 3 PACIFIC trial (NCT02125461). It showed positive results with durvalumab significantly reducing the risk of disease worsening or death for stage III unresectable lung cancer. Median PFS was 16.8 months with durvalumab vs 5.6 months with placebo. And ORR was 28.4% with durvalumab vs 16% with placebo (p \< 0.001) \[[@CR45]\]. The FDA approved durvalumab for the treatment of unresectable stage III NSCLC without progression after treatment with chemotherapy and radiation (chemoradiation) in 2018 \[[@CR46]\]. Ongoing phase 3 trials will provide illuminating data to confirm the place of durvalumab in NSCLC patients (Table [3](#Tab3){ref-type="table"}). Both as monotherapy and combination therapy in the JAVELIN Solid Tumor trial \[[@CR38]\], avelumab showed a manageable safety profile and promising clinical activity in this population of pretreated metastatic or recurrent NSCLC patients. Regarding its tolerability profile, fatigue (25%) and infusion-related reactions (19%) were the most frequent grade ≥ 3 adverse events. Despite the antitumor activity shown by avelumab in patients with advanced pretreated NSCLC patients, this novel anti-PD-L1 compound still has a long pathway to walk in order to demonstrate its potential clinical utility and own personality, for the first and second line scenario in advanced NSCLC. Ongoing studies will contribute to a better understanding of the efficacy and safety of avelumab (Table [4](#Tab4){ref-type="table"}).Table 3Ongoing phase III trials for durvalumab in non-small cell lung cancerIdentifierTitleInterventionsStudy designPopulationPrimary endpointSecondary endpointStatusPrimary CompletionNCT03800134A study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small cell lung cancer (AEGEAN)Durvalumab + platinum-based chemotherapyPlacebo + platinum-based chemotherapyRandomized parallel trialResectable stage IIA--IIIB NSCLCMPRpCR, OS, DFSRecruiting27-Jul -20NCT03519971Study of durvalumab given with chemoradiation therapy in patients with unresectable non-small cell lung cancer (PACIFIC2)Durvalumab + platinum-based chemotherapy and radiationPlacebo + platinum-based chemotherapy and radiationRandomized parallel trialUnresectable locally advanced stage III NSCLCPFS, ORROS, DOR, PFS2Recruiting30-Sep-20NCT02273375Double blind placebo controlled study of adjuvant MEDI4736 in completely resected NSCLCDurvalumabPlaceboRandomized parallel trialStage IB (\> 4 cm) to IIIA NSCLC after complete surgical resectionDFSOS, LCSSRecruitingJan-23NCT03706690A study of durvalumab as consolidation therapy in non-small cell lung cancer patients (PACIFIC5)DurvalumabPlaceboRandomized parallel trialUnresectable locally advanced stage III NSCLCPFSOS, ORR, DORRecruiting25-Mar-21NCT03164616Study of durvalumab + tremelimumab with chemotherapy or durvalumab with chemotherapy or chemotherapy alone for patients with lung cancer (POSEIDON)Durvalumab + tremelimumabDurvalumab monotherapy + SoCSoC chemotherapy aloneRandomized parallel trialUntreated advanced NSCLC without activating EGFR mutation or ALK fusionsPFS, OSORR, DOR,Recruiting30-Sep-19NCT03003962Study of durvalumab alone or chemotherapy for patients with advanced non small-cell lung cancerDurvalumabSoC chemotherapyRandomized parallel trialUntreated advanced PD-L1 positive NSCLC without EGFR mutation and ALK rearrangementOSORR, DOR, PFSActive, not recruiting30-Sep-19NCT02453282Phase III open label first line therapy study of MEDI 4736 (durvalumab) with or without tremelimumab versus soc in non-small-cell lung cancer (MYSTIC)DurvalumabDurvalumab + tremelimumabSoC chemotherapyRandomized parallel trialUntreated advanced NSCLC without activating EGFR mutation or ALK fusionsOS, PFSORRActive, not recruiting4-Oct-18NCT02542293Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)Durvalumab + tremelimumabSoC chemotherapyRandomized parallel trialUntreated advanced NSCLC without activating EGFR mutation or ALK fusionsOSPFS, ORR, DORActive, not recruiting22-Aug-19Durvalumab is currently being investigated in combination with different immunotherapies*DCR* disease control rate, *LCSS* lung cancer-specific survival, *PFS2* time from randomization to second progression, *TTD*/*TTM* time to death/time to distant metastasis, *MPR* major pathological response, *pCR* pathological, complete response, *DFS* disease-free survival Table 4Ongoing clinical trials for avelumab in non-small cell lung cancerNCT NumberTitlePhaseInterventionsStudy designPopulationPrimary endpointSecondary endpointStatusPrimary completionNCT03050554Stereotactic body radiation therapy (SBRT) combined with avelumab (anti-PD-L1) for management of early stage non-small cell lung cancer (NSCLC)I/IIAvelumab + SBRTSingle-arm trialStage I NSCLC with tumor(s) less than 5 cm in diameter or 250 cm^3^ in volumeSafety and tolerability, RFSLocoregional control, OSActive, not recruiting01-Oct-20NCT02576574Avelumab in first-line non-small cell lung cancer (JAVELIN Lung 100)IIIAvelumabPemetrexedPaclitaxelGemcitabineCarboplatinCisplatinRandomized control trialMetastatic or recurrent NSCLC without EGFR or ALKPFS, OSBOR, DOR, EQ-5D-5LActive, not recruiting07-Jun-20NCT03717155Study of avelumab and cetuximab plus gemcitabine and cisplatin in participants with squamous non-small cell lung cancer (NSCLC)IIAvelumab + cetuximab + gemcitabine + cisplatinSingle-arm trialAdvanced lung squamous carcinoma without EGFR mutation, ALK rearrangementand brain metastasisBest overall responseOccurrence of treatmentemergent adverse events, PFS, DORRecruiting25-Jan-21NCT03472560A study of avelumab in combination with axitinib in non-small cell lung cancer (NSCLC) or urothelial cancer (Javelin Medley VEGF)IIAvelumab + axitinibSingle-arm trialPretreated advanced NSCLC with no more than 2 prior lines and EGFR/ALK/ROS1 negativeORRTTR, DOR, PFSRecruiting18-Sep-20NCT02584634Study to evaluate safety, efficacy, pharmacokinetics and pharmacodynamics of avelumab in combination with either crizotinib or PF-06463922 In patients with NSCLC (Javelin Lung 101)IIAvelumabCrizotinibNon-randomized parallel trialAdvanced or metastatic NSCLC. ALK negative or positiveDLTs, ORRPFS, DOR, TTRActive, not recruiting15-Feb-19NCT03317496Safety and efficacy study of avelumab plus chemotherapy with or without other anti-cancer immunotherapy agents in patients with advanced malignanciesIIAveluma + pemetrexed/carboplatinAvelumab + gemcitabine/cisplatinNon-randomized parallel trialUntreated advanced non-squamous NSCLC without EGFR mutations or ALK rearrangementDLT, ORRPFS, DOR, TTRRecruiting04-Sep-20NCT03268057VX15/2503 in combination with avelumab in advanced non-small cell lung cancerI/IIVX15/2503 + avelumabSingle-arm trialNo prior immunotherapy treated NSCLCDLT, AEsORR, DOR, PFSRecruiting01-May-20NCT03270176A dose-finding study of the second mitochondrial activator of caspases (SMAC) mimetic debio 1143 when given in combination with avelumab to participants with advanced solid malignancies and to participants with advanced or metastatic non-small cell lung cancer (NSCLC) after platinum-based therapyIDebio 1143 + avelumabSingle-arm trialNSCLC of stage IIIB or IV (7th IASLC) that has progressed after one line of platinum containing doublet chemotherapyMaximum tolerated dose, ORRSAEs, BOR, DOR, PFS, OSRecruiting01-Sep-19NCT03158883UCDCC\#270: avelumab and stereotactic ablative radiotherapy in non-responding and progressing NSCLC patientsEarly IAvelumabStereotactic ablative radiotherapy (SAR)Non-randomized parallel trialImmunotherapy pretreated advanced NSCLC without EGFR mutations or ALK rearrangementOverall response rateOS, PFS, DCRRecruiting01-Jun-20NCT03514719PD-L1 imaging in non small cell lung cancer' (PINNACLE)IAvelumabSingle-arm trialStage IIIb/IV NSCLC or resectable stage Ia (≥ T1b tumor)---IIIa NSCLCTumor uptake of 89Zr-AvelumabCorrelation 89Zr-avelumab uptake in tumor lesions and PD-L1 expressionRecruiting31-Mar-22NCT03637491A study of avelumab, binimetinib and talazoparib in patients with locally advanced or metastatic RAS-mutant solid tumorsIIAvelumabBinimetinibTalazoparibRandomized control trialLocally advanced (primary or recurrent) or metastatic solid tumorsDLT, ORRTTR, OS, PFSRecruiting01-May-22NCT03409458A dose escalation and confirmation study of PT-112 in advanced solid tumors in combination with avelumabI/IIPT-112 + avelumabSingle-arm trialMetastatic or locally advanced diseaseRecommended doseDLTs, AEs, ORR, DCR, PFSRecruiting01-Feb-20NCT03386929Survival prolongation by rationale innovative genomicsI/IIAvelumab + axitinib + palbociclibSingle-arm trialLocally advanced or metastatic NSCLCDLT, RR, PFS, OSIncidence of treatment-related and or biopsy-related serious adverse eventsRecruiting01-Dec-21Avelumab showed a manageable safety profile and promising clinical activity in pretreated metastatic or recurrent NSCLC patients*PFS* progression-free survival, *OS* overall survival, *ORR* objective response rate, *DLT* dose-limiting toxicities, *DOR* duration of response, *TTR* time to response, *BOR* best overall response, *TEAE* treatment of adverse events

Immune checkpoint inhibitor in NSCLC with CNS metastasis {#Sec5}
========================================================

Central nerve system (CNS) metastasis is quite common in advanced NSCLC. And about 40% driver mutation negative patients would suffer from it \[[@CR47]\]. Local treatment for CNSs locus has limited efficacy in survival time extension \[[@CR48]\]. Systematic immunotherapy has been an important part for advanced NSCLC, but the efficacy in CNSs metastasis patients is still under exploring. A retrospective research conducted in Israel found that nivolumab can provide equal survival benefits for patients with or without CNS metastasis (median OS: 7.0 m vs 5.2, p = 0.5) \[[@CR49]\], which means both intracranial and extracranial lesions can benefit from ICIs. For pretreated, stable and asymptomatic CNS involved patients, atezolizumab and nivolumab seems to be good choices. In OAK trials, atezolizumab provided nearly double median OS than docetaxel for CNS involved patients (20.1 m vs 11.9 m, HR 0.54; 0.31--0.94 95% CI) and longer median time to develop new CNS diseases (not reach vs 9.5 m) \[[@CR12]\]. In ASCO 2016, a sum-analysis of checkmate 017/057/063 revealed that nivolumab can prolong survival time (8.4 m vs 6.2 m) with less irAEs comparing to docetaxel \[[@CR50]\], and the similar results were achieved by EAP program with more cases in Italy \[[@CR51]\]. Keynote 024 is a trial of first line treatment including CNS metastasis patients \[[@CR20]\]. 18 patients with CNS metastasis harboring high PD-L1 (TPS ≥ 50%) in pembrolizumab group have better PFS and OS data than the other 10 patients in chemotherapy. In a perspective phase 2 study for pembrolizumab including 18 stable brain metastasis patients with PD-L1 positive (TPS ≥ 1%), the response rate among them is 33% \[[@CR52]\], indicating the pembrolizumab is work for selected CNS related patients. Accordingly, though lacking enough perspective evidence, ICIs as monotherapy in advanced NSCLC with brain metastasis has been proved preliminarily.

Radiotherapy is standard local treatment for brain metastatic lesions. To our knowledge, radiation induced inflammatory can promote necrosis of tumor and tumor-associated antigen presented, and further activates T-cell in anticancer immunity \[[@CR53]\]. Thence, combination of immunotherapy and radiotherapy may play a synergistic role in advanced NSCLC therapy, which were improved by a secondary analysis of keynote 001 \[[@CR54]\]. Herein, the question is whether the adding ICIs would help to add more benefits for CNS metastatic patients. In Pacific study, less new brain diseases were found in arm durvalumab (5.5% vs 11.0%) \[[@CR55]\], suggesting that combination of extracranial radiotherapy and ICIs would help to control brain metastasis. Chen et al. reported that patients with brain metastasis in melanoma, nephroma and NSCLC can have significant survival benefits from concurrent immunoradiotherapy comparing to radiotherapy alone or asynchronous immunoradiotherapy (median OS: 24.7 m vs 12.9 m vs 14.5 m) \[[@CR56]\]. In a retrospective research including 17 CNS related NSCLC patients, 48% 6-month intracranial ORR was achieved \[[@CR57]\]. However, efficacy is varied according to the order of radiation and ICIs. 57% 6-month intracranial ORR was seen in patients who received radiation before or during immunotherapy while 0% in after, indicating processing radiotherapy before or during immunotherapy has better efficacy. Beside efficacy, safety is another important area needs to be explored in depth. Hubbeling HG et al. found that treatment with ICIs and brain radiation wouldn't improve incidence of radiation related adverse effects (AEs) significantly and no difference in AEs rate base on the order of treatment \[[@CR58]\]. However, another retrospective analysis reported that taking ICIs as monotherapy after gamma knife will increase the risk of radionecrosis of intracranial lesion to 37.5% \[[@CR59]\]. Thence, combination of immunotherapy and radiotherapy should be carefully selected. Herein, we are looking forward the perspective trails (NCT02978404, NCT02858869), which are conducting for exploring more evidences in the combination of immunotherapy and radiotherapy, to answer the questions in fractionation schedule, radiation dose, target volume and patient selection. More combination strategies for ICIs and other therapies in advanced NSCLC with CNS metastasis are still under exploring. A sub-analysis of keynote 189 with 109 brain metastasis patients, combination of pembrolizumab and chemotherapy significantly extents OS comparing to monochemotherapy. NCT0296993 is a trail for exploring double ICIs plus radiotherapy and NCT02681549 is for combination of immunotherapy and bevacizumab (Table [5](#Tab5){ref-type="table"}).Table 5Ongoing trials for evaluating combination strategies of checkpoints inhibitor in advanced NSCLC with brain metastasisIdentifierTitlePhasePopulationArmsPrimary endpointSecondary endpointStatusPrimary completionNCT02978404Combining radiosurgery and nivolumab in the treatment of brain metastasesIIStage IV NSCLC or ccRCC with brain metastasisNivolumab (240 mg IV q2 week or 480 mg IV q4 week) and Radiosurgery \[15--20 Gray (Gy) in 1 fraction\]Intracranial PFSTreated brain lesions control rate, OS, PFS, neurocognitive function, toxicity and etcRecruiting1-Jun-21NCT02858869Pembrolizumab and stereotactic radiosurgery for melanoma or non-small cell lung cancer brain metastasesINSCLC or melanoma with brain metastasisArm A (pembrolizumab, SRS 6 Gy)Proportion of dose limiting toxicitiesORR, OS, rate of local recurrence and etcRecruiting1-Oct-20Arm B (pembrolizumab, SRS 9 Gy)Arm C (pembrolizumab, SRS 18--21 Gy)NCT02696993Nivolumab and radiation therapy with or without ipilimumab in treating patients with brain metastases from non-small cell lung cancerI/IIStage IV NSCLC with brain metastasisArm A (nivolumab, SRS)RP2D and Intracranial PFSNeurocognitive changesRecruiting31-Dec-20Arm B (nivolumab, WBRT)Arm C (nivolumab, ipilimumab, SRS)Arm D (nivolumab, ipilimumab, WBRT)NCT02681549Pembrolizumab plus bevacizumab for treatment of brain metastases in metastatic melanoma or non-small cell lung cancerIINSCLC or melanoma with brain metastasisPembrolizumab plus bevacizumabBMRRORR, PFS, safety and toxicity, biomarkers for efficacy predictionRecruiting1-May-21Systematic immunotherapy has been an important part for advanced NSCLC, but the efficacy in CNSs metastasis patients is still under exploring*RP2D* recommended phase 2 dose, *BMRR*, brain metastasis response rate, *SRS* stereotactic radiosurgery, *WBRT* whole-brain radiotherapy

Neoadjuvant immune checkpoint inhibitors in NSCLC {#Sec6}
=================================================

Surgery is the only radical treatment strategy for resectable NSCLC currently \[[@CR60]\]. However, 5-year survival rate after surgery is low, vary from 19 to 73% \[[@CR61]\]. Theoretically, neoadjuvant therapy can eliminate micro-metastatic diseases before surgery to reduce the rate of recurrence. However, preoperative chemotherapy could only increase 5% survival benefits \[[@CR62]\]. As for perioperative radiotherapy, it helps to improve local control rate, but seems to contribute nothing to survival benefits \[[@CR63]\]. Immune checkpoint inhibitors have the opportunity break the bottleneck of current neoadjuvant therapy. Forde et al. firstly reported a pilot study of nivolumab as neoadjuvant therapy for stage II--IIIA NSCLC \[[@CR8]\]. After taking 2 cycles nivolumab, 20/21 patients received operation, 45% (9/20 cases) major pathological response (MPR) was achieved with acceptable side-effect profile. Moreover, 15/20 patients are disease-free and alive for 30 months \[[@CR64]\]. Tumor specific T-cell clones were observed in both resected samples and peripheral blood samples, indicating that ICIs can activate T cells systematically to eliminate both primary and metastatic tumors including micro-metastasis, which was more significant in MPR patients. Comparing to the expression of PD-L1, TMB is better for MPR prediction. Recently, an extended analysis of this study indicates that ctDNA and peripheral T cell expansion are potential biomarkers for response and surveillance prediction \[[@CR64]\]. Interestingly, there is great disunity between pathologic and radiologic diagnosis in the evaluation of immune neoadjuvant therapy efficacy (RECIST: 2/20 PR, 18/20 SD; Pathology: 9/20 MPR), suggesting that current RECIST standard is not suitable for evaluation. The percentage change of standard uptake value (SUV) in positron-emission tomography scan (PET/CT) could be a better evaluation standard for neoadjuvant immunotherapy since it reflects the metabolic activity of cell, which is corresponded to pathological response \[[@CR65]\]. According to the interim analysis of LCM3, atezolizumab is effective and safe as neoadjuvant therapy for stageIB to selected IIIB NSCLC patients \[[@CR66]\]. Among 82 resected patients, 15 cases (18%) achieved MPR with only 6% grade 3/4 treatment related adverse effects occurred. Interestingly, biomarkers for MPR prediction are quite different to Forde PM's study. MPR rate is not significantly different between PD-L1 negative and positive (cutoff: 1%; clone sp142, 2/26 vs 10/35, p = 0.055). However, it is meaningful in low and high expression (cutoff: TPS = 50%; clone 22c3, 5/44 vs 7/20, p = 0.040). Moreover, median TMB (10.4 Mut/Mb) is not different in patients with MPR or not. Thus, patient selection for neoadjuvant immunotherapy is still controversial. Several ongoing trials are further exploring the dose, administration time, safety and efficacy of neoadjuvant ICIs for early stage NSCLC (LCM3 for atezolizumab, NEOSTAR for nivolumab, MK3475-223 for pembrolizumab).

Given the excellent synergistic effects of the combination of immunotherapy and other therapies in advanced NSCLC, several trials have been designed to evaluate the feasibility and safety of combination strategies in neoadjuvant therapy. Results of NADIM (NCT 03081689) presented in ASCO 2019 demonstrated that 41/46 stage IIIA patients were performed R0 resection after 3 cycles neoadjuvant immunochemotherapy (nivolumab + paclitaxel + carboplatin), 34 patients (83%) achieved MPR including 24 (71%) of them were complete pathologic response (pCR). Moreover, 90% patients experienced downstaging \[[@CR67]\]. MK-3475-671 is a double blind phase III study in comparing the efficacy of perioperative pembrolizumab or placebo plus platinum based neoadjuvant chemotherapy for stageIIB orIIIA NSCLC, which will answer the question whether patients can earn more benefits from adding ICIs in neoadjuvant chemotherapy. As we know from keynote-001, prior radiation would prolong PFS for patients received ICIs. Ongoing pilot trials NCT 03237377 is exploring the safety of neoadjuvant immunoradiotherapy for resectable IIIA NSCLC (durvalumab + radiation or durvalumab + termelimumab + radiation). Synergistic effect of ICIs-based combination in neoadjuvant therapy is another active research area. Data from NEOSTAR (ASCO 2019), higher median percentage of non-viable tumor (viable tumor: 20% vs 65%, p = 0.095) and of tissue residual memory TILs (CD3+:81.2% vs 54.4%, p = 0.028; CD8+: 56.2% vs 38.3%, p = 0.069) were seen in nivolumab plus ipilimumab group comparing to nivolumab alone \[[@CR68]\]. Further analysis is still ongoing. Though efficacy and safety of combination strategies were preliminarily proved, patient selection is still unclear. Therefore, more studies are required to explore better biomarkers for patient selection of combination neoadjuvant therapy.

Potential immune checkpoint inhibitors {#Sec7}
======================================

Though immune checkpoint inhibitors targeting in PD-1/L1 axis have achieved great progression in the treatment of NSCLC, the proportion of beneficiaries is still low currently \[[@CR17]\]. Recent researches in other immune checkpoints are expected to expand the population benefiting from immunotherapy. NKG2A is an intracytoplasmic tyrosine-based inhibitor motif, expressed in NK cells and selectively in CD8+ CTLs in tumor microenvironment, which can block the immune ability of NK cell and CD8+ T cell if it binds its ligand (HLA-E) overexpressed in carcinoma of lung, cervix and head/neck \[[@CR69]\]. Interestingly, anti-NKG2A antibodies can play anti-cancer role only in inflammatory tumor environment \[[@CR17]\], indicating they need to be combined with other agents to kill tumor. Monalizumab is a humanized anti-NKG2A antibody, which can enhance the anti-tumor ability of NK cells, and can rebuild the anti-tumor ability of CD8+ T cells when blocked with PD-1/PD-L1 axis at the same time. The preclinical study demonstrated that durvalumab alone can save about 40% mice from death, while combining with monalizumab can achieve an efficacy of 75% \[[@CR17]\]. In addition, its efficacy and safety were evaluated in a phase II clinical trial of monalizumab and cetuximab in the treatment of recurrent squamous cell carcinoma of the head and neck. The mid-term analysis showed that the effect of dual drug combination was better than single drug of cetuximab, with an ORR of 31% \[[@CR69]\]. As for NSCLC, one arm of PIONeeR-Clinical study is exploring the efficacy of combination of durvalumab and monalizumab in advanced NSCLC resistance to ICIs. And the efficacy in neoadjuvant therapy for NSCLC is evaluating in NeoCOAST. Ecto-5′-nucleotidase (CD73) is an enzyme highly expressed in anergic T cell, which degenerates AMP to adenosine leading to inhibit CTLs function in anticancer immunity. Additionally, CD73 can induce angiogenesis and lymphangiogenic to promote the development and progression of tumor \[[@CR16]\]. Therefore, antibody targeting in CD73 would inhibit the growth of cancer through reducing the production of adenosine to relieve its inhibitory function in CTLs and blocking angiogenesis and lymphangiogenic. Indeed, preclinical studies have demonstrated the anti-cancer abilities of anti-CD73 antibodies in several kinds of cancer. MEDI9447 (oleclumab) is a humanized anti-CD73 antibody \[[@CR70]\]. Given the anti-cancer ability of oleclumab alone or in combination with durvalumab in vivo and animal model, a phaseIstudy (NCT02503774) is conducting for evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab in adult subjects with select advanced solid tumors. However, since CD73 is involved in homeostasis regulation such as epithelial barrier function and intestinal secretion and reabsorption function, attention should be paid to the possible adverse effects when using CD73 \[[@CR16]\].

Adaptive resistance to PD-1/L1 inhibitors is hampering the further progress of immunotherapy \[[@CR14]\]. Koyama et al. reported that the selective activation of T-cell immunoglobulin mucin-3 (TIM3) is the key mechanism of resistance of anti-PD-1 immunotherapy \[[@CR15]\]. Mice models (lung cancer) revealed that CD8+ T cells would fail after anti-PD-1 resistance, which was related to the up-regulation of multiple immune checkpoints expression, especially TIM3. Furthermore, mice can earn more survival time from sequential blocking therapy with TIM3 after anti-PD-1 treatment than anti-PD-1 alone (11.9 weeks vs 5 weeks, p = 0.0008). Additionally, high levels of TIM3, rather than other immune markers, were detected in T cells of NSCLC patients who had been treated with anti-PD-1 and developed drug resistance. Therefore, inhibiting TIM3 would help to overcome the adaptive resistance to anti-PD-1. An interim analysis of AMBER study, posted in SITC 2018 meeting \[[@CR71]\], revealed that for patients with advanced NSCLC after resistance to PD-1/L1 antibody, 9% ORR was achieved by 100 mg TSR-022 (anti-TIM3) combined with 500 mg TSR-042 (anti-PD-1) and 15% by each 300 mg, with acceptable adverse effects (6.7% grade ≥ 3). It is worth mentioning that for those expressed more than 1% of PD-L1 in both groups, total ORR reached 33%.

Great proportion of patients treated with single agents PD-1/L1 inhibitors could not develop durable anticancer response because of the inability to produce long-term immunological T cell memory. Current studies on costimulatory pathway demonstrated great potential to improve efficacy of checkpoint inhibition and induce durable anticancer response. GITR \[glucocorticoid-induced tumor necrosis factor receptor (TNFR)--related protein\] belongs to TNFR super family, which can activate anticancer ability of CD4+ and CD8+ T cells and block the inhibitor effect of Treg on CTLs \[[@CR72]\]. Previous clinical studies revealed limited efficacy in monotherapy with agonists of GITF, but great potential value in combination of agonist of GITR and anti-PDl/L1. MEDI1873 (GITR agonist) was proved to activate CD4+ T cell in peripheral blood and eliminate Treg intratumor (NCT02583165), while TRX518 (GITR agonist) is able to clear Treg cells but unable to reverse the deletion of CD8+ T cells without combination with PD-1 antibody (NCT02628574). Wang et al. found that activating GITR combined with blocking PD1 can effectively reverse the depletion of CD8+ T cells and maintain the phenotype of memory T cells. The clearance of Treg by GITR antibody provided immune activation relief to CD8+ T cells, and the proliferation of CD8+ T cells intratumor was significant \[[@CR73]\]. Results from ASCO 2018 meeting, revealed that under the condition of 170 mg alone and 60 mg in combination, MK-1248 (GITR agonist) had good tolerance, no dose-limiting toxicity and no treatment-related death for advanced solid cancer \[[@CR74]\]. AS soon as combined with pembrolizumab, the therapeutic response was observed (1CR, 2PR; NCT02553499) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Immune checkpoints with potential therapeutic value in NSCLC. Reported immune checkpoints inhibitors with therapeutic value in NSCLC are illustrated. Because of the limited beneficiary population and resistance to ICIs against PD1/L1 axis, novel agents targeting in other immune checkpoints are developed to overcome the currently limitation of ICIs. After the recognition of TCR and MHC, costimulatory factors help to regulate the activation of T cells. The stimulation of positive checkpoints and inhibition of negative checkpoints are to maintain or recover the anticancer ability of T cells. Antibodies targeting negative checkpoints (PD-1/PD-L1, TIM-3/Galectin, NKG2A/HLA-E, CD73) are to release the inhibition of T cells, while agonists of positive checkpoints (GITR/GITRL) are to strengthen the activation of T cells

Conclusion {#Sec8}
==========

The rapid progression of immunotherapy in recent years has broken through the bottleneck of cytotoxicity-based chemotherapy in wild-type non-small cell lung cancer and improved the prognosis and life quality for patients. However, due to the little effective population of single drug treatment, the clinical application of ICIs is greatly limited. Synergistic effects in combination based on ICIs are expanding the beneficiary population. To be noticed, there are still lots of problems being eager to answers, such as the patient selection for best combination strategy, the identification of pseudoprogression, administration sequencing and so on. Moreover, combinations of PD-1/L1 blockage and novel immune checkpoint inhibitor targeting other than PD-1/L1 axis are preliminary proved to be worth looking forward to overcome primary or adaptive resistance of anti-PD-1/L1 antibodies. Predictably, more novel agents and combination strategies will help to NSCLC treatment. However, how to achieve precise immunotherapy for maximizing the benefits of patients is worthy of our in-depth exploration in the future.
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